Shanghai Fosun Pharmaceutical's (HKG:2196) subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical received approval from China's National Medical Products Administration to conduct a clinical trial of DM1001 Formulation for the treatment of signs and symptoms of Parkinson's disease, according to a Friday Hong Kong bourse filing.
The company plans to commence a Phase I clinical trial in China once relevant conditions are met.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments